Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus Capecitabine in Advanced/Metastatic Breast Cancer
NCT00662025Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in breast cancer, sponsored by Pfizer. Primary endpoint: Objective Response Rate (Data Review Committee). Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00662025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662025.